Kolexia
Dubruille Viviane Hématologie
Dubruille Viviane
Hématologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
168 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie myéloïde Leucémie myéloïde chronique BCR-ABL positive Lymphomes Myélofibrose primitive Myélome multiple Maladie du greffon contre l'hôte Anémie Leucémie aigüe myéloïde

Collaborateurs

Voir plus
Blin Nicolas
Blin Nicolas
Hôpital Hôtel-Dieu Nantes, Nantes, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Mahe Beatrice
Mahe Beatrice
Hôpital Hôtel-Dieu Nantes, Nantes, France
Gastinne Thomas
Gastinne Thomas
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Novartis
39 collaboration(s)
Dernière en 2023
ICON CLINICAL RESEARCH SARL
5 collaboration(s)
Dernière en 2021
B3TSI
4 collaboration(s)
Dernière en 2021
Pfizer
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System: Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Essai Clinique (CHU Poitiers)   19 mars 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
American journal of hematology   02 janvier 2024
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM): A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy
Essai Clinique (GSK)   30 octobre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023
Quad-class exposed/refractory myeloma is associated with short survival.
British journal of haematology   13 octobre 2023
HILDEGAZ: Phase 1 Dose Escalation of Early Infusion of Zoledronic Acid in Combination With Increasing Low-dose of Interleukin-2 in Order to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allogeneic Stem Cell Transplantation (SCT)
Essai Clinique (CHU Nantes)   05 octobre 2023
MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen.
Haematologica   20 juillet 2023